ELMA SLOUGH: Open Payments
NPI 1982220588 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,342 in 47 payments from 8 companies in 2025. Trend: 2023 $677 · 2024 $1,241 · 2025 $1,342
Food & beverage: $1,230Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $304 |
| Teva Pharmaceuticals USA, Inc. | 13 | $299 |
| Vanda Pharmaceuticals Inc. | 2 | $235 |
| ABBVIE INC. | 13 | $191 |
| Neurocrine BioSciences, Inc. | 1 | $122 |
| Supernus Pharmaceuticals, Inc. | 7 | $108 |
| Lundbeck LLC | 2 | $53 |
| Novo Nordisk Inc | 1 | $30 |
Products named: REXULTI, FANAPT, VRAYLAR, AUSTEDO XR, INGREZZA, Qelbree, Wegovy, ABILIFY MAINTENA.
Industry payments across CA — which companies pay providers there.
